Luc serves as a Managing Partner at Droia Ventures, a venture capital firm specializing in genetic diseases and oncology, with over €600 million in assets. He represents Droia on the boards of Montis Biosciences, Vaderis, Volastra, Muna, Quralis, Vico Therapeutics, and Alesta.
Anaheim Bio secures €40 million in Series A funding to advance its preclinical-stage biotechnology research. The Leiden, Netherlands-based company leverages the capital to support development in its early-stage pipeline. Investors back the firm’s focus on innovative biotech solutions.
Anaheim Bio secures €40 million in Series A funding to progress its lead drug, ANA-1, into clinical trials for treating calcium pyrophosphate deposition (CPPD) disease. The company spun out of Alesta Therapeutics ahead of its acquisition by BioMarin, focusing on developing therapies for rare metabolic disorders.